Johnson & Johnson

Posted by & filed under Accounting Information Systems, Accounting Principles, Advanced Accounting, All Articles, Auditing, Cost Accounting, Ethical Dilemma, Financial Accounting, Financial Statement Analysis, Income Taxes, International Accounting, Managerial Accounting, Uncategorized.

According to Douglas House, a new analysis has been released that shows patients with type 2 diabetes (T2D) that are treated with Johnson & Johnson (JNJ) unit Janssen Pharmaceuticals’ INVOKANA (canagliflozin) experienced significantly less risk of cardiovascular (CV) death or hospitalization for heart failure (HHF).

Questions:

  1. Based on the data, what is the reduction of fatal heart failure?
  2. Where was the study published and where was it presented?
  3. Does the company have the permission to market it as a cardiovascular reduction drug?
  4. What effect do you think this will have on the stock price of (JNJ) and why?

House, D. (2017). Johnson & Johnson’s Invokana lowers risk of CV death or hospitalization in T2D. Seaking Alpha news blog, March 12 (Retrievable online at https://seekingalpha.com/news/3338393-johnson-and-johnsons-invokana-lowers-risk-cv-death-hospitalization-t2d?app=1&uprof=14&dr=1#email_link)